API | bexagliflozin

bexagliflozin (Brenzavvy) Report issue

Small molecule Approved ^FDA

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Chemistry

SMILES: OC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2
InChIKey: BTCRKOKVYTVOLU-SJSRKZJXSA-N
Mol. Mass: 464.94
ALogP: 2.0 Partition coefficient
ChEMBL Molecule:
bexagliflozin

More Chemistry

Pharmacology

Mechanism of Action:
- Sodium/glucose cotransporter 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

bexagliflozin | egt0001442 | egt-0001442 | egt-1442 | thr-1442

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (1)

Diabetes Mellitus, Type 2 (approved 2023)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 3)

Essential Hypertension (Phase 2/Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 18
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue